Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration

Open access

Abstract

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older individuals worldwide. The disease is characterized by abnormal extracellular deposits, known as drusen, that accumulate along the basal surface of the retinal pigmented epithelium. Although drusen deposition is common in older individuals, large numbers of drusen and/or extensive areas of confluent drusen represent a significant risk factor for AMD. Widespread drusen deposition is associated with retinal pigmented epithelial cell dysfunction and degeneration of the photoreceptor cells of the neural retina. Recent studies have shown that drusen contain a variety of immunomodulatory molecules, suggesting that the process of drusen formation involves local inflammatory events, including activation of the complement cascade. Similar observations in Alzheimer's disease (AD) have lead to the hypothesis that chronic localized inflammation is an important element of AD pathogenesis, with significant neurodegenerative consequences. Accordingly, the amyloid beta (Aβ) peptide, a major constituent of neuritic plaques in AD, has been implicated as a primary activator of complement in AD. Here we show that Aβ is associated with a substructural vesicular component within drusen. Aβ colocalizes with activated complement components in these “amyloid vesicles,” thereby identifying them as potential primary sites of complement activation. Thus, Aβ deposition could be an important component of the local inflammatory events that contribute to atrophy of the retinal pigmented epithelium, drusen biogenesis, and the pathogenesis of AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.192203399

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 9

  1. G S Hageman, P J Luthert, N H V Chong, L V Johnson, D H Anderson, R F Mullins Progr. Ret. Eye Res., eds N N Osborne, G J Chader (Elsevier Science, London) 20, 705–732 (2001).
  2. H Lin, D O Clegg Invest Ophthalmol Visual Sci 39, 1703–1712 (1998).
  3. K S Kim, D L Miller, V J Sapienza, C M J Chen, C Bai, I Grundke-Iqbal, J R Currie, H M Wisniewski Neurosci Res Comm 2, 121–130 (1988).
  4. K S Kim, G Y Wen, C Bancher, C M J Chen, V J Sapienza, H Hong, H M Wisniewski Neurosci Res Commun 7, 113–122 (1990).
  5. D A Simpson, S Feeney, C Boyle, A W Stitt Mol Vis 6, 178–183 (2000).
  6. C A Curcio, C L Millican, T Bailey, H S Kruth Invest Ophthalmol Visual Sci 42, 265–274 (2001).
  7. K Loeffler, D Edward, M Tso Invest Ophthalmol Visual Sci 36, 24–31 (1995).
  8. R P Burns, L Feeney-Burns Trans Am Ophthalmol Soc 78, 206–225 (1980).
  9. R J Ulshafer, C B Allen, B Nicolaissen, M L Rubin Invest Ophthalmol Visual Sci 28, 683–689 (1987).

Cited by

See all 447

Metadata

Authors
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H.
Affiliations
  • University of California, Santa Barbara (US)
  • Johns Hopkins University (US)
Venue
Proceedings of the National Academy of Sciences
Published
2002-08-20
Volume
99
Issue
18
Pages
11830-11835
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2003101845
Cited by
447
References
45
Citations by year
2026: 11 · 2025: 12 · 2024: 14 · 2023: 8 · 2022: 17 · 2021: 20 · 2020: 20 · 2019: 14 · 2018: 19 · 2017: 26 · 2016: 24 · 2015: 34 · 2014: 38 · 2013: 21 · 2012: 23
FWCI
8.33
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Eye Institute (R01EY011521, EY 11-521, R01EY011527, EY11527)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
Keywords
amyloid-beta, complement activation, age-related macular degeneration, drusen, retinal pigment epithelium, neuroinflammation, retinal aging, neuritic plaques, complement proteins
MeSH terms
Aged, Aged, 80 and over, Aging, Base Sequence, Complement Activation, Humans, Immunohistochemistry, Macular Degeneration, Middle Aged, Polymerase Chain Reaction, Amyloid beta-Peptides, DNA Primers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. https://app.cochat.ai/papers/10.1073/pnas.192203399
The paper
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002). The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.192203399

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.